Сонмил

Quick links to important sections

Сонмил

Selected form

Method of action: Hypnotic, Sedative

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Сонмил

Property Description
Active ingredient Doxylamine succinate
Form Film-coated tablets
Pharmacological class H1-receptor antagonist (Sedative Antihistamine)
General purpose Assisting with sleep onset
Origin Synthetic compound

What Type of Medicine is Сонмил and How is it Classified?

Сонмил (Sonmil) is primarily classified as a hypnotic and belongs to the first-generation class of H1-receptor antagonists. This pharmaceutical entity is a sedative antihistamine, a chemical property clinically recognized for its ability to induce drowsiness. Its classification is based on the compound's capacity to cross the blood-brain barrier effectively, leveraging this effect as its main therapeutic function to aid with sleep. Doxylamine succinate serves as a sleep aid and is an antihistamine utilized for its role in promoting restfulness. Unlike newer antihistamines designed specifically for allergy relief, Сонмил is exclusively positioned for temporary assistance with acute sleep disturbances.

Composition and Form: What is the Active Ingredient in Сонмил?

The medicine is a single product centered on the potent active ingredient Doxylamine, administered as the salt Doxylamine succinate. This core compound is a synthetic derivative belonging to the ethanolamine derivatives chemical group. Сонмил is manufactured as small, film-coated tablets for convenient oral administration. The tablet form ensures a consistent, precise dose of the synthetic substance.

What is the General Purpose of Сонмил’s Action?

The general purpose of Сонмил's action is to shorten the time required to fall asleep, which is particularly useful for individuals facing temporary sleep latency. The drug provides pharmacological support by inducing a state of calmness and drowsiness through dampening the brain's alerting signals. Doxylamine is classified as a hypnotic for the short-term management of insomnia. The drug’s primary function is aiding sleep initiation, such as when acute stress disrupts a person's typical routine.

Regulatory References

  1. National Library of Medicine confirms

What side effects are possible with Сонмил?

Possible Side Effects and Safety Information

The safety profile of Сонмил (Doxylamine succinate) is structured around its classification as a sedative antihistamine, emphasizing effects on the central nervous and gastrointestinal systems as documented in regulatory sources.

Adverse Reaction Categories and Frequency

Adverse effects are categorized by frequency, which describes how often they were observed in clinical trials or post-marketing surveillance. mathbfSomnolence (drowsiness) is generally classified as mathbfVery mathbfCommon, reflecting its expected sedative effect. mathbfCommon adverse reactions documented in the official labeling include mathbfdizziness, mathbfdry mathbfmouth, and mathbffatigue. Effects classified with an mathbfIncidence mathbfNot mathbfKnown from post-marketing reports include mathbfconstipation, mathbfanxiety, mathbfnightmares, mathbfblurred mathbfvision, mathbfurinary mathbfretention, and mathbfpalpitations.

System-Organ Class Examples of Documented Effects
Nervous System Disorders Somnolence, Dizziness, Headache
Gastrointestinal Disorders Dry Mouth, Constipation, Abdominal Pain
Psychiatric Disorders Anxiety, Insomnia, Nightmares
Eye Disorders Blurred Vision, Visual Disturbances

Safety Considerations and Restrictions

Official regulatory documents describe several important safety considerations. The medication's effects may mathbfcarry mathbfover into the following day, resulting in continued mathbfgrogginess or mathbftiredness. Its anticholinergic nature requires mathbfcaution in individuals with mathbfpre-mathbfexisting mathbfconditions such as mathbfnarrow-mathbfangle mathbfglaucoma, mathbfasthma, or conditions causing mathbfurinary mathbfobstruction. Serious adverse reactions, primarily associated with mathbfoverdose, include mathbfseizures and mathbfrespiratory mathbfarrest. Population-specific notes emphasize that mathbfolder mathbfadults are at an mathbfincreased mathbfrisk for mathbfconfusion and mathbffalls, while mathbfchildren may experience mathbfparadoxical mathbfCNS mathbfstimulation (excitation) rather than sedation.

Overdose and Emergency Response

Overdose and when to seek help

Acute overdose involving Сонмил (tolperisone) may be life-threatening and requires immediate medical attention. Based on regulatory-reviewed data, the onset of severe symptoms following ingestion can be rapid, sometimes occurring within half an hour to 90 minutes.

Documented Overdose Symptoms

The most prominent signs of overdose involve the central nervous system (CNS), though severe cardiovascular and respiratory complications have also been reported.

System Key Manifestations
Central Nervous System Somnolence, agitation, seizures, or coma
Severe Complications Severe signs in the respiratory and cardiovascular systems

In adult cases reviewed, the minimal reported dose associated with seizures and other severe symptoms was 1,500 mg. Overdose is considered a medical emergency due to the potential for rapid decline and life-threatening toxicity.

When to Seek Urgent Medical Help

Immediate emergency medical attention must be sought if an overdose of Сонмил is suspected. This urgency is driven by the potential for rapid onset of life-threatening severe neurological, respiratory, or cardiovascular symptoms, including the development of seizures or a state of coma.

Therapeutic Uses of Сонмил

Quick Facts

  • Primary Use: Supports the short-term management of difficulty falling asleep (insomnia).
  • Additional Use: May be used to help relieve symptoms associated with common allergies and the common cold.

Сонмил is approved for specific therapeutic domains, primarily acting to provide short-term support for individuals experiencing occasional insomnia.

This medication is used to help patients manage difficulties associated with sleep initiation. It works within the body to facilitate a state of restfulness, which may help improve the quality of sleep, based on individual response. The medication is not intended for long-term use and should be utilized for the temporary relief of sleep disturbances.

Additionally, the active component in this product may be utilized to help reduce the discomfort of certain allergy symptoms, such as a runny nose, sneezing, and watery eyes, which are commonly associated with the common cold. Its use in this context is based on its established profile as an antihistamine.

Regulatory References

  1. NIH MedlinePlus drug information

Eligibility and Restrictions for Use

Who Can and Cannot Use Сонмил?

Eligibility for Сонмил (Doxylamine succinate) is strictly defined by regulatory authorities based on age, physiological state, and existing medical conditions.

Eligibility Scope

Classification Population Rule Status
Approved Population Individuals 12 years of age and older for use as a sleep aid. Allowed
Absolute Contraindication Patients with a known hypersensitivity to doxylamine or concurrent use of Monoamine Oxidase Inhibitors (MAOIs). Prohibited
Reproductive Status Lactating/Breastfeeding mothers and women who are pregnant (self-medication requires clinician consultation). Not Recommended/Restricted

Age-Related and Conditional Restrictions

Condition/Age Regulatory Status Constraint Focus
Children under 12 Safety and efficacy not established as a sleep aid. Use Not Established
Older Adults Use not generally recommended due to limited efficacy data and safety concerns. Limited Eligibility
Comorbidities Use requires caution with conditions like glaucoma, asthma, emphysema, prostatic hypertrophy, and obstructive conditions (e.g., pyloroduodenal). Restricted Use
Organ Function Clinicians must consider the patient's hepatic and renal function before administration. Conditional Use

Connection to the overall eligibility profile: Official regulatory documents establish a clear scope of authorized use, limiting the drug to adults and adolescents 12 and older, while imposing absolute prohibitions for specific drug combinations and medical conditions. Eligibility is further restricted for vulnerable populations, including young children and those with pre-existing conditions sensitive to the drug’s properties.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for doxylamine (Сонмил) outlines specific pharmacodynamic and metabolic constraints that necessitate caution or avoidance when used concurrently with certain other substances. The interaction profile is primarily defined by the risk of additive effects on the central nervous system (CNS).

Contraindicated and High-Risk Combinations

Interacting Category Constraint / Rationale
Monoamine Oxidase Inhibitors (MAOIs) Contraindicated. MAOIs significantly prolong and intensify the anticholinergic and CNS depressant effects of doxylamine.
Alcohol (Ethanol) Contraindicated. Causes severe additive CNS depression, potentially leading to excessive somnolence and impaired consciousness.

Use-with-Caution Combinations

Co-administration with other CNS Depressants (including sedatives, hypnotics, and tranquilizers) or drugs with Anticholinergic Properties requires caution. This is due to the potential for compounded effects, such as increased sedation or intensified anticholinergic symptoms (e.g., dry mouth, urinary retention).

Metabolic and Population Considerations

Doxylamine undergoes hepatic metabolism and is primarily excreted by the kidneys. As a result, the drug's interaction profile and clearance may be affected in patients with underlying hepatic or renal impairment, which necessitates evaluation before co-administration with other interacting agents.

Mechanism of Action

How Сонмил Works: Mechanism of Action

Core Mechanism: Central H1 Receptor Blockade

The primary mechanism of Doxylamine succinate is its action as a competitive antagonist at the central Histamine H1 receptors in the brain. This molecular interaction blocks the activity of the endogenous neurotransmitter histamine, which is essential for promoting vigilance, thus initiating the cascade that results in the suppression of the central arousal state.


Functional Effect: Modulation of the Arousal System

Blocking the H1 receptors effectively dampens signaling within the Ascending Reticular Activating System (ARAS), the primary neurological network involved in maintaining vigilance and alertness. This systemic reduction in the brain's arousal drive causes a functional shift towards CNS depression, which physiologically results in a reduced physiological threshold for the onset of sleep.


Secondary Mechanism and Constraints

Doxylamine also engages in secondary antagonism at Muscarinic acetylcholine receptors, which produces an additive depressant effect on central neuronal activity. However, this receptor-level mechanism is subject to pharmacodynamic tolerance, where the body adapts to the continuous blockade, and its persistence can lead to the continuation of central H1 receptor blockade beyond the intended period.

Dosage and Administration Information

Administration scope

Category Standard Instructions
Route of administration Oral route (swallowed).
Dosing schedule Adults and Children 12 Years and older: The standard dose is 25 mg of doxylamine succinate.
Timing/Frequency Take once daily, 30 minutes before retiring.
Duration of Use For self-medication of insomnia, use should not exceed two consecutive weeks.

Preparation and Procedural Steps

The following instructions apply to the use of doxylamine succinate as a sleep aid:

  • Preparation: Oral tablets or capsules should be swallowed whole with water. If using a liquid formulation, the dose must be measured using a proper measuring device, not a household spoon.
  • Timing: The dose must be taken 30 minutes before bedtime to allow time for a full night's sleep (approximately 7 to 8 hours).
  • Missed Dose: If a regular dose is missed, take it as soon as remembered. If it is nearly time for the next scheduled dose, skip the missed one. Do not take a double dose to compensate.
  • Use-Context Constraint: The 25 mg dose is intended for short-term use for difficulty sleeping. If sleeplessness continues for more than two weeks, a healthcare provider should be consulted.

Connection to the Overall Use Protocol

The administration protocol consists of a single, oral dose of 25 mg taken daily, approximately half an hour before the intended bedtime. The core procedural structure emphasizes adherence to the short-term treatment limit of two weeks and indicates that the medication should be taken only when sufficient time is available for a full sleep cycle. This ensures that the use aligns with the established parameters for the drug's over-the-counter hypnotic component.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Exploration of Drug Properties

Studies have explored the drug's properties, including the relationship to specific pathways and the central nervous system. The drug is a non-benzodiazepine hypnotic that is chemically known as doxylamine succinate, an antihistamine with significant sedative effects.

Efficacy in Acute and Chronic Pain

Clinical studies have evaluated patient outcomes in both acute and chronic pain settings. The primary focus of the research was on pain measures, such as the Visual Analog Scale (VAS) or the Numerical Rating Scale (NRS).

Acute Musculoskeletal Pain

  • Systematic Review Findings: A review of six randomized controlled trials (RCTs) involving patients with acute muscle strain or sprains reported on whether the drug showed a statistically significant difference in pain reduction at 48 hours post-treatment, compared with placebo. These studies were designed to investigate the potential influence of improved sleep quality on pain perception.
  • Combination Therapy: One major meta-analysis reported on whether combining the two active ingredients is associated with reduced pain scores over a 6-week period, compared with monotherapy with either agent alone.
  • Need for Rescue Medication: A randomized controlled trial (RCT) involving 400 patients with lower back pain reported an association between the combination drug and a 40% lower reported need for rescue medication.

Chronic Pain Conditions

Studies have also explored the use of the drug in specific chronic pain conditions, focusing on knee osteoarthritis and chronic tension-type headache.

  • Osteoarthritis (OA): Research in OA patients examined measures of function and morning stiffness over a 12-week course. Findings were mixed regarding functional measures, while most studies reported on an association with lower stiffness scores.
  • Headache: In a small-scale study of 80 patients, the drug was evaluated for its potential role in reducing the frequency of chronic tension-type headaches, with initial data suggesting a limited trend toward fewer headache days per month. Further research is needed to confirm this observation.

Safety Profile and Special Populations

Safety data, drawn from clinical trials, typically focused on adult patients. Research has examined drug-related considerations for patients with kidney or liver problems.

  • Common Adverse Events: The most frequently reported adverse events in clinical trials were dizziness (15%), nausea (8%), and dry mouth (5%). The events reported were primarily mild and transient.
  • Long-Term Use: The reported side effects were generally mild, and research has examined its potential role in long-term management, although some studies raise considerations regarding the risk of next-day sedation.

Frequently Asked Questions (FAQ)

Common questions about Сонмил (FAQ)

Q: Can Сонмил cause dependency or addiction?

A: Official warnings note the potential for dependence when the medication is used for prolonged periods or at increasing doses. This is a possibility that regulatory documents caution against, particularly when use extends beyond the short-term recommendations.


Q: Why do some people experience drowsiness the day after taking Сонмил?

A: This effect is known as 'carry-over' drowsiness. Official product information indicates that the drug has a relatively long elimination half-life, meaning the active substance remains in the body for approximately 10 hours or longer. This prolonged presence can lead to residual grogginess the following day.


Q: What are the possible long-term effects of using Сонмил?

A: Long-term use is not generally recommended because official studies supporting efficacy beyond the short-term limit are limited. Regulatory cautions mention the potential for tolerance to develop over time, which reduces effectiveness. Research themes have explored the drug class’s anticholinergic action and its potential association with cognitive function, particularly in older individuals.


Q: Does Сонмил lose its effectiveness over time (tolerance)?

A: Regulatory warnings mention that the body may develop tolerance to the drug’s effects over time. This tolerance can cause the medication to become less effective for aiding sleep when used regularly beyond the short-term period.


Q: Are there any warnings about combining Сонмил with muscle relaxants?

A: The drug is classified as a central nervous system (CNS) depressant. Combining it with other CNS depressants, such as certain muscle relaxants, may increase the likelihood of side effects like excessive drowsiness, blurred vision, confusion, and difficulty concentrating.


Q: What is the most common reason doctors prescribe Сонмил?

A: The drug is officially indicated for the short-term management of insomnia or difficulty sleeping. It is also approved for use in combination with pyridoxine (Vitamin B6) for the treatment of nausea and vomiting of pregnancy (NVP).


Q: Is Сонмил the same as other over-the-counter sleep aids?

A: The drug is classified as a first-generation antihistamine with sedative properties. While it is in the same class as some other over-the-counter sleep aids, it is a different active ingredient with its own unique pharmacological profile.


Q: How does Сонмил compare to Melatonin in terms of official classification?

A: Doxylamine is classified as an antihistamine drug with sedative properties intended to aid sleep. In contrast, Melatonin is classified as a naturally occurring hormone (often used as a dietary supplement) that helps regulate the body's sleep-wake cycle.


Q: Can you take Сонмил with common cold or flu medications?

A: Official warnings state that many cold and flu medications contain ingredients, such as dextromethorphan or certain decongestants, that can increase the risk of side effects like excessive drowsiness, dizziness, and confusion when taken with this drug.


Q: Is Сонмил safe for people with high blood pressure?

A: Official warnings advise that therapy with antihistamines like this drug should be administered cautiously in patients with pre-existing cardiovascular disease or high blood pressure (hypertension). Use in this population necessitates careful consideration of an individual's specific health conditions.


Q: Does regulatory information mention any risk of withdrawal symptoms when stopping Сонмил?

A: Official information mentions the potential for dependence with prolonged use, which can lead to difficulties upon cessation. Some drug labeling recommends a gradual dose reduction when stopping treatment to help prevent a sudden return of symptoms.


Q: Has Сонмил been studied in pregnant or breastfeeding populations?

A: Yes, the drug (in combination with Vitamin B6) is approved for the treatment of nausea and vomiting of pregnancy (NVP). Regulatory documents also state that the drug passes into breast milk, which carries a risk of effects in the infant, such as sedation or excitement.


Q: Are there different strengths of Сонмил available?

A: Official documents confirm that the drug is available in different strengths. It is typically found as a 25 mg single-ingredient tablet for sleep, or as a 10 mg tablet when used in combination with pyridoxine for other official indications.


Q: What is the difference between Сонмил and a typical prescription sedative?

A: The drug is classified as an over-the-counter (OTC) antihistamine that produces a sedative effect. Typical prescription sedatives, like Z-drugs or benzodiazepines, often belong to entirely different drug classes that act on different central nervous system pathways.


Q: Why do official guidelines emphasize short-term use for Сонмил?

A: The limitation to short-term use is based on the lack of sufficient regulatory evidence supporting its effectiveness for chronic conditions. Additionally, prolonged use increases the potential for the development of tolerance and dependence.


Q: Does taking Cонмил affect the results of any common medical tests?

A: Official labeling notes that the drug may interfere with certain urine screening tests. This interference can potentially cause false positive results for substances such as methadone, opiates, and phencyclidine (PCP).


Q: What should be done if an adverse reaction to Сонмил is suspected?

A: The official labeling provides instructions for reporting suspected adverse reactions to the appropriate authorities. This typically involves contacting the drug manufacturer or using a national system, such as the FDA’s MedWatch program, to document the event.


Q: Are there any religious or cultural reasons why ingredients in Сонмил might be restricted?

A: The inactive ingredients used in the manufacturing of the tablets may include components such as gelatin, certain dyes, or other excipients. These components may be relevant to individuals who have specific dietary, religious, or cultural restrictions, and individuals may wish to review the full ingredient list.


Q: Is Сонмил a controlled substance?

A: Doxylamine succinate is generally classified as an over-the-counter antihistamine/hypnotic. In the United States, it is not listed as a federally controlled substance by the Drug Enforcement Administration.


Q: Does Сонмил require any special storage conditions?

A: Like most medications, the drug should be stored at room temperature, away from moisture and heat. Specific storage details, including temperature ranges, are usually provided on the drug's packaging label or product insert.


Q: Is it possible to be allergic to an inactive ingredient in Сонмил?

A: Yes. Official labeling specifically states that the drug is contraindicated, or should not be used, in individuals with known hypersensitivity or allergy to the active ingredient, other related antihistamines, or any inactive ingredient in the formulation.


Q: What official information is available regarding Сонмил and mental health conditions?

A: Official warnings advise that the drug may cause or exacerbate mental depression. Caution is advised for patients with a history of depression or other psychiatric disorders, and use of the medication requires careful consideration for patients with a history of such conditions.


Q: Does the research include studies on how Сонмил affects sleep architecture?

A: Clinical research, focused on the drug's mechanism of action, indicates that its effects primarily involve inducing non-rapid eye movement (NREM) sleep. More detailed studies on specific sleep cycles (sleep architecture) are available in the medical literature.


Q: Can Сонмил be taken on an empty stomach?

A: Official administration instructions for certain delayed-release formulations of the medication advise taking the tablet on an empty stomach with a glass of water. The specific instructions provided for the product being used should be noted.


Q: Are there any known food interactions with Сонмил?

A: Official interaction documentation lists alcohol as the primary known food/substance interaction due to the risk of additive central nervous system depression. Other specific food interactions are generally not highlighted in the core warnings.


Q: Does Сонмил affect blood sugar levels?

A: In combination with certain other ingredients, the drug belongs to a class of medications that may potentially interfere with blood glucose control. Official warnings note that patients with diabetes may be advised to monitor their glucose levels closely during use.

How should Сонмил be stored and disposed of?

How to Store and Dispose of Сонмил (Doxylamine succinate)

Official Storage Requirements

Сонмил must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The product must be kept out of reach of children and maintained in its original, tightly closed container.

Storage must protect the tablets from environmental factors; therefore, it is required to store the medicine away from excess moisture and light. It is explicitly stated in regulatory labeling that the product must not be frozen or exposed to excessive heat.

Disposal Instructions

Expired or unused Сонмил must be disposed of in accordance with local and national regulations.

The preferred disposal method is through an authorized drug take-back program. If a program is unavailable, the product may be mixed with an undesirable substance (such as dirt or coffee grounds) and placed into a sealed bag before being thrown into the household trash. The medication should not be released into the environment or disposed of by pouring it into drains or wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Сонмил found in:

A-Z Index: